Requires medicaid and insurers to include coverage for testing of PFAS levels in blood; defines PFAS.
Summary
This bill would require most New York health insurance policies that provide medical, major medical, or similar comprehensive coverage to cover blood testing for PFAS levels when ordered by a physician or other licensed health care provider authorized under state law. It applies the same requirement to medical expense indemnity corporations and health service corporations, and it defines PFAS as perfluoroalkyl and polyfluoroalkyl substances.
The bill also amends the Medicaid-related provisions of the social services law to include PFAS blood testing as a covered medical assistance service, but only if federal financial participation is available. If federal matching funds are not available for the testing, Medicaid coverage would not be required for that service. The bill would take effect on the first January 1 after enactment and would apply to policies and contracts issued, renewed, modified, altered, or amended on or after that date.
Impact
The bill would expand coverage obligations under the Insurance Law by adding PFAS blood testing to mandated benefits for individual, group, and nonprofit health coverage arrangements. It would also amend the Social Services Law to make PFAS testing a covered Medicaid service subject to federal funding availability. Insurers, health service corporations, and Medicaid administrators would need to update coverage policies and claims processing to reflect the new mandate.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of support or opposition in the available materials. Based on the bill text and caption, the measure appears to be a public-health coverage mandate aimed at improving access to diagnostic testing for environmental exposure, with a likely consumer- and health-protection orientation.
Contention
The main policy issue embedded in the bill is cost and coverage responsibility: insurers would be required to pay for PFAS blood testing when ordered by an authorized provider, and Medicaid would cover it only if federal financial participation is available. That federal-funding شرط may be a point of contention because it limits the Medicaid mandate and could affect whether the service is actually covered statewide. Potential concerns for insurers and budget stakeholders would likely center on utilization, premium impact, and whether the testing is medically necessary in enough cases to justify a mandate.
Further providing for legislative purpose, for definitions, for lead poisoning prevention, assessment and testing and for blood lead assessment and testing coverage.
Requires health insurance plans to provide coverage for continuous blood glucose monitors for all children; requires coverage for glucose monitoring devices for all sugar disorders.